Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Summer 2018 was a season of surprises - mostly great ones - for cannabis investing.
Not long ago, few foresaw Corona's parent corporation Constellation Brands Inc. (NYSE: STZ) investing $3.8 million in what was already the world's biggest cannabis producer in its second deal together in less than a year...
Or Coca-Cola Co. (NYSE: KO) starting negotiations with a cannabis company about a potential CBD-based beverage...
Or a British pharmaceutical developer getting the first U.S. Food & Drug Administration approval for a cannabis-based medicine.
Yet every one of those events happened... in short order.
With each time, cannabis stocks soared accordingly, especially for the companies directly involved.
Big news means major moves when it comes to cannabis investing.
But what I see as the biggest, most shocking developments of late haven't been happening in a board room. They've been happening in the shadows of the Capitol in Washington, D.C.
The U.S. cannabis policy thaw is already underway, and the ongoing developments associated with it are going to be game-changers for investors who don't wait for too long on the sidelines.
These are first-time events that herald a brand-new era of cannabis profits for shareholders.
We're talking about real movement in the slow and steady end of the longtime federal prohibition of marijuana.
Here are the three things I'm watching closest...
About the Author
Greg Miller started working on Wall Street in September, 1987, just a month before the “Black Monday” stock market crash.
During his career there, he became an expert in just about every kind of publicly traded security - from blue-chip and small-cap stocks to municipals, junk bonds, and derivatives. As a portfolio manager, Greg was responsible for over $500 million of assets in mutual funds and insurance company accounts.
After leaving the Street, he designed a successful options trading strategy and made lucrative tech investments for a financial publication. He has also helped develop new products and worked with other editors to hone their strategies. He’s always been dedicated to deep, fundamental research - and he always will be - because he believes buying the very best companies at the right price is the best way to amass wealth in the stock market.